European Pharmaceutical Innovation

Novo Nordisk licensed its experimental Parkinson's cell therapy to AI-native biotech Cellular Intelligence and shut its internal cell therapy unit, refocusing on GLP-1 as its core franchise. Shares rose 24.9% over 30 days as investors backed the pivot. The move positions Europe's largest pharma company as a model for AI-outsourced drug R&D.

Novo Nordisk posted strong Q1 2026 earnings and saw its stock rise 25% over 30 days after pivoting to a licensing-first model in cell therapy. The Danish pharma giant shut its internal cell therapy unit and handed Parkinson's disease development to Cellular Intelligence, an AI-platform company. The move reflects a broader European shift toward AI-native drug discovery infrastructure.